Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005 Sep 20;46(6):986-93
Date
09/20/2005Pubmed ID
16168280DOI
10.1016/j.jacc.2004.08.070Scopus ID
2-s2.0-24944494905 (requires institutional sign-in at Scopus site) 192 CitationsAbstract
Acute coronary syndromes and other manifestations of atherothrombotic disease are primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or subocclusive thrombus formation. Platelets play a critical role in the pathophysiology of atherothrombotic disease, and aspirin is the most commonly used antiplatelet agent. Clinical trials have demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. Despite its proven benefit, the absolute risk of recurrent vascular events among patients taking aspirin remains relatively high, an estimated 8% to 18% after two years. Therapeutic resistance to aspirin might explain a portion of this risk. Although formal diagnostic criteria and a validated method of measurement are lacking, aspirin resistance may affect between 5% and 45% of the population. Given the prevalence of cardiovascular disease, the potential impact of aspirin resistance is large. Currently, however, there are many unanswered questions regarding the biological mechanism, diagnosis, population prevalence, clinical relevance, and optimal therapeutic intervention for aspirin resistance.
Author List
Mason PJ, Jacobs AK, Freedman JEAuthor
Peter Mason MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AspirinAtherosclerosis
Drug Resistance
Humans
Platelet Activation
Thrombosis